Lyell Immunopharma, Inc.
Lyell Immunopharma reports promising ronde-cel trial results.
1 source·08/12, 11:20·sec.gov
Bylaws amended; no immediate financial impact.
1 source·05/12, 21:06·sec.gov
10-Q form submitted!
1 source·12/11, 21:53·sec.gov
Company announces Q3 2025 financial results.
1 source·12/11, 21:14·sec.gov
Lyell Immunopharma signs exclusive licensing agreement with ICT.
1 source·10/11, 12:34·sec.gov
Leadership changes in financial positions announced.
1 source·03/11, 13:32·sec.gov
CFO Charles Newton resigns, consulting until 2026.
1 source·16/09, 20:24·sec.gov
10-Q form submitted!
1 source·12/08, 20:16·sec.gov
Routine financial results announcement.
1 source·12/08, 20:13·sec.gov
Private placement raises $50 million for clinical trials.
1 source·25/07, 12:06·sec.gov
Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive Appointments
·finviz.com·09/06, 20:08